AngioDynamics Narrows Losses to $10.2M Amid Restructuring Efforts
Ticker: ANGO · Form: 10-K · Filed: Jul 18, 2025 · CIK: 1275187
| Field | Detail |
|---|---|
| Company | Angiodynamics Inc (ANGO) |
| Form Type | 10-K |
| Filed Date | Jul 18, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Medical Devices, Earnings Report, Restructuring, Net Loss, Revenue, Healthcare, Financial Performance
Related Tickers: ANGO
TL;DR
**ANGO is still losing money, but the massive reduction in losses suggests a potential turnaround is brewing; watch for sustained revenue growth.**
AI Summary
AngioDynamics Inc. reported a net loss of $10.2 million for the fiscal year ended May 31, 2025, a significant improvement from the $107.6 million net loss in fiscal year 2024. This improvement was primarily driven by a decrease in acquisition, restructuring, and other net charges, which fell to $1.5 million in fiscal 2025 from $98.7 million in fiscal 2024. Revenue for fiscal year 2025 was $275.8 million, a slight decrease from $280.1 million in fiscal year 2024, reflecting ongoing market challenges. The company's strategic outlook focuses on optimizing its product portfolio and improving operational efficiency, as evidenced by the reduced restructuring charges. Despite the net loss, the substantial reduction in non-recurring expenses indicates a move towards financial stabilization. AngioDynamics continues to invest in its core medical device segments, aiming for long-term growth and profitability.
Why It Matters
AngioDynamics' reduced net loss to $10.2 million from $107.6 million signals a potential turning point for investors, indicating that past restructuring efforts are beginning to yield results. This financial improvement could stabilize the company's competitive position in the medical device market, particularly against larger rivals, by freeing up capital for innovation and market expansion. For employees, it suggests greater job security and a more stable operational environment. Customers may benefit from a more focused product portfolio and potentially enhanced service as the company streamlines its operations. The broader market will watch if AngioDynamics can sustain this positive trend and return to profitability, impacting investor sentiment for mid-cap medical technology firms.
Risk Assessment
Risk Level: medium — AngioDynamics reported a net loss of $10.2 million for fiscal year 2025, indicating continued unprofitability. While an improvement from the $107.6 million loss in fiscal year 2024, the company still faces challenges in achieving sustained profitability and revenue growth, with revenue slightly decreasing from $280.1 million to $275.8 million.
Analyst Insight
Investors should monitor AngioDynamics' next few quarterly reports for consistent revenue growth and further reductions in net losses. A sustained trend of profitability and positive cash flow would signal a stronger buy opportunity, while continued revenue stagnation or renewed losses would warrant caution.
Financial Highlights
- revenue
- $275.8M
- net Income
- -$10.2M
- revenue Growth
- -1.5%
Key Numbers
- $10.2M — Net Loss (Significantly reduced from $107.6M in FY24, indicating improved financial performance.)
- $275.8M — Revenue (Slight decrease from $280.1M in FY24, highlighting ongoing top-line challenges.)
- $1.5M — Acquisition, Restructuring, and Other Net Charges (Substantially lower than $98.7M in FY24, driving the reduction in net loss.)
- 89.9% — Reduction in Net Loss (Calculated as (($107.6M - $10.2M) / $107.6M) * 100, showing significant improvement.)
- 1.5% — Revenue Decrease (Calculated as (($280.1M - $275.8M) / $280.1M) * 100, indicating a slight decline.)
Key Players & Entities
- ANGIODYNAMICS INC (company) — filer of 10-K
- $10.2 million (dollar_amount) — net loss for fiscal year 2025
- $107.6 million (dollar_amount) — net loss for fiscal year 2024
- $1.5 million (dollar_amount) — acquisition, restructuring, and other net charges in fiscal year 2025
- $98.7 million (dollar_amount) — acquisition, restructuring, and other net charges in fiscal year 2024
- $275.8 million (dollar_amount) — revenue for fiscal year 2025
- $280.1 million (dollar_amount) — revenue for fiscal year 2024
- Bloomberg (company) — financial news organization
- SEC (regulator) — Securities and Exchange Commission
- Latham, NY (location) — AngioDynamics business address
FAQ
What was AngioDynamics' net loss for fiscal year 2025?
AngioDynamics reported a net loss of $10.2 million for the fiscal year ended May 31, 2025, a substantial improvement from the $107.6 million net loss in fiscal year 2024.
How did AngioDynamics' revenue change in fiscal year 2025?
AngioDynamics' revenue for fiscal year 2025 was $275.8 million, a slight decrease from $280.1 million reported in fiscal year 2024.
What contributed to the reduction in AngioDynamics' net loss?
The significant reduction in AngioDynamics' net loss was primarily due to a decrease in acquisition, restructuring, and other net charges, which fell to $1.5 million in fiscal 2025 from $98.7 million in fiscal 2024.
What is AngioDynamics' strategic outlook based on the 10-K filing?
AngioDynamics' strategic outlook focuses on optimizing its product portfolio and improving operational efficiency, as evidenced by the reduced restructuring charges and efforts to move towards financial stabilization.
What are the key risks for AngioDynamics investors?
A key risk for AngioDynamics investors is the company's continued unprofitability, despite the reduced net loss, and the challenge of achieving sustained revenue growth, as revenue slightly decreased in fiscal year 2025.
Where is AngioDynamics Inc. headquartered?
AngioDynamics Inc. is headquartered at 14 Plaza Drive, Latham, NY 12110, as stated in its 10-K filing.
When was AngioDynamics' fiscal year 2025 10-K filed?
AngioDynamics' 10-K for the fiscal year ended May 31, 2025, was filed on July 18, 2025, with the SEC.
What was the impact of restructuring on AngioDynamics' financials?
Restructuring efforts significantly impacted AngioDynamics' financials by reducing acquisition, restructuring, and other net charges from $98.7 million in fiscal 2024 to $1.5 million in fiscal 2025, directly contributing to the improved net loss.
Is AngioDynamics profitable?
No, AngioDynamics is not profitable, reporting a net loss of $10.2 million for fiscal year 2025, although this is a substantial improvement from the $107.6 million net loss in the prior fiscal year.
What is the significance of the reduced net loss for AngioDynamics?
The reduced net loss to $10.2 million signifies that AngioDynamics' efforts to streamline operations and reduce non-recurring expenses are yielding results, potentially indicating a path towards future profitability and improved financial health.
Risk Factors
- Competition and Market Acceptance [high — market]: The medical device market is highly competitive, with established players and emerging companies. AngioDynamics faces challenges in gaining market share and ensuring widespread adoption of its products, particularly in the face of evolving clinical practices and technological advancements. Failure to innovate or effectively market its offerings could lead to declining revenues.
- Regulatory Compliance and Approvals [high — regulatory]: As a medical device company, AngioDynamics is subject to stringent regulations from bodies like the FDA. Obtaining and maintaining regulatory approvals for new products and ensuring ongoing compliance with manufacturing and quality standards are critical. Delays or failures in regulatory processes can significantly impact product launch timelines and market access.
- Profitability and Cash Flow [medium — financial]: The company has reported net losses in recent fiscal years, including $10.2 million in FY2025. While this is an improvement from FY2024's $107.6 million loss, sustained profitability remains a key concern. The ability to generate positive cash flow from operations is essential for funding ongoing research and development, capital expenditures, and debt obligations.
- Supply Chain and Manufacturing [medium — operational]: Disruptions in the supply chain or manufacturing processes can impact the availability and cost of raw materials and finished goods. AngioDynamics relies on a complex network of suppliers and internal manufacturing capabilities. Any significant interruption could lead to production delays, increased costs, and an inability to meet customer demand.
- Product Liability and Litigation [medium — legal]: Medical devices carry inherent risks, and AngioDynamics could face product liability claims or other litigation. Adverse legal judgments or settlements could result in significant financial costs and reputational damage, impacting the company's financial stability and operational focus.
Industry Context
AngioDynamics operates within the highly competitive medical device industry, specifically focusing on minimally invasive therapies. The sector is characterized by rapid technological innovation, stringent regulatory oversight, and a constant drive for improved patient outcomes. Companies in this space must balance R&D investment with market access and commercialization strategies to succeed.
Regulatory Implications
The company's operations are heavily influenced by regulatory bodies such as the FDA. Compliance with quality system regulations, pre-market approval processes, and post-market surveillance are critical. Any failure to meet these standards can lead to product recalls, fines, or suspension of manufacturing, directly impacting revenue and profitability.
What Investors Should Do
- Monitor revenue trends closely.
- Assess the sustainability of reduced restructuring charges.
- Evaluate the company's product pipeline and market penetration.
Glossary
- Acquisition, Restructuring, and Other Net Charges
- These are costs associated with significant corporate events such as mergers, acquisitions, divestitures, or major internal reorganizations. They can include severance costs, integration expenses, and asset impairment charges. (A substantial decrease in these charges from $98.7 million in FY2024 to $1.5 million in FY2025 was the primary driver for the significant reduction in the company's net loss, indicating a move towards operational streamlining.)
Year-Over-Year Comparison
In fiscal year 2025, AngioDynamics Inc. reported a net loss of $10.2 million, a significant improvement from the $107.6 million net loss in fiscal year 2024. This was largely due to a substantial reduction in acquisition, restructuring, and other net charges, which decreased from $98.7 million to $1.5 million. However, revenue experienced a slight decline of 1.5%, falling from $280.1 million in FY2024 to $275.8 million in FY2025, indicating ongoing challenges in top-line performance despite improved cost management.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on July 18, 2025 regarding ANGIODYNAMICS INC (ANGO).